MCP110 is primarily used in the field of cancer research and therapy. It functions as an inhibitor of the Ras-Raf interaction, which is a critical pathway in the development and progression of various cancers. By disrupting this interaction, MCP110 can potentially halt the uncontrolled cell growth and division that characterize cancerous tumors. This makes it a valuable compound in the study of targeted cancer treatments, particularly for cancers driven by mutations in the Ras pathway, such as pancreatic, lung, and colorectal cancers. Researchers are exploring its efficacy in preclinical models to assess its potential as a therapeutic agent, either alone or in combination with other cancer drugs.